Editing Buspirone (section)

====Sexual dysfunction====
There is some evidence that buspirone on its own may be useful in the treatment of [[hypoactive sexual desire disorder]] (HSDD) in women.<ref name="pmid27916394">{{cite journal |vauthors=Goldstein I, Kim NN, Clayton AH, DeRogatis LR, Giraldi A, Parish SJ, Pfaus J, Simon JA, Kingsberg SA, Meston C, Stahl SM, Wallen K, Worsley R |title=Hypoactive Sexual Desire Disorder: International Society for the Study of Women's Sexual Health (ISSWSH) Expert Consensus Panel Review |journal=Mayo Clinic Proceedings |volume=92 |issue=1 |pages=114–128 |date=January 2017 |pmid=27916394 |doi=10.1016/j.mayocp.2016.09.018 |doi-access=free }}</ref> Buspirone may also be effective in treating [[antidepressant]]-induced [[sexual dysfunction]].<ref name=Wil2018/><ref name="pmid34247952">{{cite journal |vauthors=Trinchieri M, Trinchieri M, Perletti G, Magri V, Stamatiou K, Cai T, Montanari E, Trinchieri A |title=Erectile and Ejaculatory Dysfunction Associated with Use of Psychotropic Drugs: A Systematic Review |journal=The Journal of Sexual Medicine |volume=18 |issue=8 |pages=1354–1363 |date=August 2021 |pmid=34247952 |doi=10.1016/j.jsxm.2021.05.016 |s2cid=235798526 |quote=Buspirone, a non-benzodiazepine anxiolytic, have even demonstrated enhancement of sexual function in certain individuals. For this reason, they have been proposed as augmentation agents (antidotes) or substitution agents in patients with emerging sexual dysfunction after treatment with antidepressants.}}</ref><ref name="pmid31591339">{{cite journal |vauthors=Montejo AL, Prieto N, de Alarcón R, Casado-Espada N, de la Iglesia J, Montejo L |title=Management Strategies for Antidepressant-Related Sexual Dysfunction: A Clinical Approach |journal=Journal of Clinical Medicine |volume=8 |issue=10 |date=October 2019 |page=1640 |pmid=31591339 |pmc=6832699 |doi=10.3390/jcm8101640 |doi-access=free }}</ref>